Fresenius Medical Care AG & Co. (NYSE:FMS)‘s stock had its “neutral” rating reissued by stock analysts at Royal Bank of Canada in a note issued to investors on Wednesday.

A number of other research analysts also recently issued reports on FMS. Zacks Investment Research upgraded shares of Fresenius Medical Care AG & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 3rd. Credit Suisse Group downgraded shares of Fresenius Medical Care AG & Co. from an “outperform” rating to a “neutral” rating in a research report on Thursday, July 5th. Bank of America started coverage on shares of Fresenius Medical Care AG & Co. in a research report on Monday, July 9th. They issued a “buy” rating on the stock. DZ Bank restated a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research report on Monday, August 6th. Finally, HSBC upgraded shares of Fresenius Medical Care AG & Co. from a “hold” rating to a “buy” rating in a research report on Tuesday, August 28th. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Fresenius Medical Care AG & Co. has an average rating of “Buy” and a consensus price target of $60.00.

NYSE:FMS opened at $49.86 on Wednesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.11 and a current ratio of 1.37. Fresenius Medical Care AG & Co. has a one year low of $47.49 and a one year high of $57.94. The company has a market cap of $31.52 billion, a P/E ratio of 22.56, a price-to-earnings-growth ratio of 2.44 and a beta of 0.80.

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its earnings results on Tuesday, July 31st. The company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.06). Fresenius Medical Care AG & Co. had a return on equity of 10.78% and a net margin of 11.65%. The business had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.28 billion. During the same quarter in the prior year, the business earned $0.89 earnings per share. The firm’s quarterly revenue was down 5.7% on a year-over-year basis. On average, analysts expect that Fresenius Medical Care AG & Co. will post 2.46 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Northern Trust Corp lifted its position in shares of Fresenius Medical Care AG & Co. by 2.5% in the 2nd quarter. Northern Trust Corp now owns 838,500 shares of the company’s stock worth $42,219,000 after purchasing an additional 20,391 shares during the period. Royal Bank of Canada increased its stake in shares of Fresenius Medical Care AG & Co. by 5.8% in the 1st quarter. Royal Bank of Canada now owns 590,198 shares of the company’s stock valued at $30,148,000 after acquiring an additional 32,612 shares in the last quarter. Aperio Group LLC increased its stake in shares of Fresenius Medical Care AG & Co. by 6.5% in the 2nd quarter. Aperio Group LLC now owns 254,964 shares of the company’s stock valued at $12,837,000 after acquiring an additional 15,616 shares in the last quarter. Millennium Management LLC increased its stake in shares of Fresenius Medical Care AG & Co. by 80.8% in the 1st quarter. Millennium Management LLC now owns 146,984 shares of the company’s stock valued at $7,508,000 after acquiring an additional 65,707 shares in the last quarter. Finally, Ferguson Wellman Capital Management Inc. bought a new stake in shares of Fresenius Medical Care AG & Co. in the 2nd quarter valued at $7,359,000. Hedge funds and other institutional investors own 2.46% of the company’s stock.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S.

Featured Story: Fundamental Analysis – How It Helps Investors

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.